Principal Financial Group Inc Sarepta Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q4 2024

A detailed history of Principal Financial Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 282,084 shares of SRPT stock, worth $29.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

282,084

Holding current value

$29.1 Million

% of portfolio

0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Jan 31, 2025	BUY	$104.54 - $137.94 $29.5 Million - $38.9 Million	282,084 New	282,084 $34.3 Million
Q3 2024 Oct 31, 2024	SELL	$124.33 - $156.75 $11.9 Million - $15 Million	-95,974 Reduced 26.44%	267,037 $33.4 Million
Q2 2024 Jul 29, 2024	BUY	$113.33 - $163.85 $36 Million - $52 Million	317,277 Added 693.74%	363,011 $57.4 Million
Q1 2024 Apr 29, 2024	SELL	$93.7 - $141.53 $356,528 - $538,521	-3,805 Reduced 7.68%	45,734 $5.92 Million
Q4 2023 Feb 07, 2024	BUY	$67.31 - $124.76 $1.85 Million - $3.44 Million	27,549 Added 125.28%	49,539 $4.78 Million
Q3 2023 Nov 02, 2023	BUY	$102.5 - $123.59 $81,487 - $98,254	795 Added 3.75%	21,990 $2.67 Million
Q2 2023 Aug 07, 2023	BUY	$106.4 - $157.19 $17,875 - $26,407	168 Added 0.8%	21,195 $2.43 Million
Q1 2023 May 09, 2023	SELL	$117.53 - $155.99 $279,603 - $371,100	-2,379 Reduced 10.16%	21,027 $2.9 Million
Q4 2022 Feb 09, 2023	BUY	$100.86 - $132.13 $352,203 - $461,397	3,492 Added 17.54%	23,406 $3.03 Million
Q3 2022 Nov 09, 2022	SELL	$75.71 - $119.24 $112,126 - $176,594	-1,481 Reduced 6.92%	19,914 $2.2 Million
Q2 2022 Aug 10, 2022	BUY	$62.69 - $88.44 $247,061 - $348,542	3,941 Added 22.58%	21,395 $1.6 Million
Q1 2022 May 09, 2022	SELL	$63.15 - $90.42 $74,011 - $105,972	-1,172 Reduced 6.29%	17,454 $1.36 Million
Q4 2021 Feb 09, 2022	SELL	$77.28 - $99.42 $399,769 - $514,299	-5,173 Reduced 21.74%	18,626 $1.68 Million
Q3 2021 Nov 09, 2021	SELL	$65.97 - $92.48 $196,788 - $275,867	-2,983 Reduced 11.14%	23,799 $2.2 Million
Q2 2021 Aug 10, 2021	SELL	$69.38 - $86.75 $4,370 - $5,465	-63 Reduced 0.23%	26,782 $2.08 Million
Q1 2021 May 10, 2021	BUY	$72.25 - $168.95 $108,953 - $254,776	1,508 Added 5.95%	26,845 $2 Million
Q4 2020 Feb 08, 2021	BUY	$125.56 - $178.74 $26,242 - $37,356	209 Added 0.83%	25,337 $4.32 Million
Q3 2020 Nov 06, 2020	SELL	$127.12 - $172.34 $268,604 - $364,154	-2,113 Reduced 7.76%	25,128 $3.53 Million
Q2 2020 Aug 05, 2020	BUY	$93.0 - $171.7 $725,679 - $1.34 Million	7,803 Added 40.14%	27,241 $4.37 Million
Q1 2020 May 12, 2020	BUY	$82.38 - $131.64 $62,855 - $100,441	763 Added 4.09%	19,438 $1.9 Million
Q4 2019 Feb 05, 2020	SELL	$76.53 - $135.58 $7,806 - $13,829	-102 Reduced 0.54%	18,675 $2.41 Million
Q3 2019 Nov 13, 2019	SELL	$72.81 - $156.91 $202,630 - $436,680	-2,783 Reduced 12.91%	18,777 $1.42 Million
Q2 2019 Aug 12, 2019	BUY	$112.21 - $151.95 $148,117 - $200,573	1,320 Added 6.52%	21,560 $3.28 Million
Q1 2019 May 10, 2019	BUY	$106.67 - $151.68 $313,396 - $445,635	2,938 Added 16.98%	20,240 $2.41 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $194,931 - $297,966	-2,003 Reduced 10.38%	17,302 $1.89 Million
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $89,595 - $125,493	777 Added 4.19%	19,305 $3.12 Million
Q2 2018 Aug 13, 2018	SELL	$71.74 - $153.69 $101,727 - $217,932	-1,418 Reduced 7.11%	18,528 $0
Q1 2018 May 14, 2018	BUY	$54.02 - $82.27 $28,630 - $43,603	530 Added 2.73%	19,946 $1.48 Million
Q4 2017 Feb 13, 2018	BUY	$47.64 - $56.75 $502,268 - $598,315	10,543 Added 118.82%	19,416 $1.08 Million
Q3 2017 Nov 02, 2017	BUY	$35.73 - $47.15 $317,032 - $418,361	8,873	8,873 $402,000

Others Institutions Holding SRPT

# of Institutions

536

Shares Held

87.4M

Call Options Held

1.55M

Put Options Held

1.35M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.02B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Sarepta Therapeutics, Inc. Transaction History